• Australia

Australian Pharma Stocks Analysis

ASX:AGN
ASX:AGN
ASX:AGNPharmaceuticals

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

August 12, 2022
We can readily understand why investors are attracted to unprofitable companies. By way of example, Argenica...
ASX:MYX
ASX:MYX
ASX:MYXPharmaceuticals

Mayne Pharma Group Limited's (ASX:MYX) market cap touched AU$652m last week, benefiting both individual investors who own 56% as well as institutions

August 11, 2022
A look at the shareholders of Mayne Pharma Group Limited ( ASX:MYX ) can tell us which group is most powerful. The...
ASX:RNO
ASX:RNO
ASX:RNOPharmaceuticals

Insiders may be rethinking their AU$2.2m Rhinomed Limited (ASX:RNO) investment now that the company has lost AU$5.7m in value

August 11, 2022
The recent price decline of 11% in Rhinomed Limited's ( ASX:RNO ) stock may have disappointed insiders who bought...
ASX:IHL
ASX:IHL
ASX:IHLPharmaceuticals

Incannex Healthcare Limited's (ASX:IHL) 18% gain last week benefited both individual investors who own 55% as well as insiders

August 10, 2022
A look at the shareholders of Incannex Healthcare Limited ( ASX:IHL ) can tell us which group is most powerful. And the...
ASX:SPL
ASX:SPL
ASX:SPLPharmaceuticals

Insiders purchases in Starpharma Holdings Limited (ASX:SPL) last year yet to pay off, remain down AU$65k despite recent gains

August 08, 2022
Insiders who bought AU$168k worth of Starpharma Holdings Limited ( ASX:SPL ) stock in the last year recovered part of...
ASX:IDT
ASX:IDT
ASX:IDTPharmaceuticals

After a 15% dip, insiders are undoubtedly glad they sold IDT Australia Limited (ASX:IDT)

July 29, 2022
Over the past year, insiders sold AU$175k worth of IDT Australia Limited ( ASX:IDT ) stock at an average price of...
ASX:RCE
ASX:RCE
ASX:RCEPharmaceuticals

We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely

July 28, 2022
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
ASX:NEU
ASX:NEU
ASX:NEUPharmaceuticals

The five-year returns have been incredible for Neuren Pharmaceuticals (ASX:NEU) shareholders despite underlying losses increasing

July 25, 2022
We think all investors should try to buy and hold high quality multi-year winners. And we've seen some truly amazing...
ASX:PXS
ASX:PXS
ASX:PXSPharmaceuticals

Pharmaxis Ltd (ASX:PXS) insiders recover some losses but still AU$33k away from matching original investment

July 25, 2022
Insiders who purchased AU$113k worth of Pharmaxis Ltd ( ASX:PXS ) shares over the past year recouped some of their...
  • 1
  • 2
  • 3
  • 4
  • 5
Next

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.

Simply Wall Street Pty Ltd
17-21 Bellevue Street, Surry Hills, Sydney
Download on the App StoreGet it on Google Play
  • About
  • Company
  • Careers
  • Plans
  • Log In
  • Help Centre
  • Latest Coverage
  • Podcasts
  • Financial Services Guide
  • Terms and Conditions
  • Privacy Policy

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.